

What is claimed is:

1. An agent for preventing recurrence of cerebrovascular disorder or an agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof which comprises a compound having an angiotensin II antagonistic activity, a prodrug thereof or a salt thereof.


2. The agent according to claim 1, wherein the compound having an angiotensin II antagonistic activity is a non-peptide compound.

3. The agent according to claim 1, wherein the compound having an angiotensin II antagonistic activity is a compound having an oxygen atom in the molecule.

4. The agent according to claim 1, wherein the compound having an angiotensin II antagonistic activity is a compound having an ether bond or a carbonyl group.

5. The agent according to claim 1, wherein the compound having an angiotensin II antagonistic activity is a compound represented by the formula (I):

2003-01-08 09:00



wherein R^1 represents a group capable of forming an anion or being converted into said group, X indicates that the phenylene group and the phenyl group are bound to each other directly or via a spacer of a chain made of 2 or less
 5 atoms, n is an integer of 1 or 2, ring A represents a benzene ring which may further have substituent(s), R^2 represents a group capable of forming an anion or being converted into said group, and R^3 represents a hydrocarbon residue which may be bound via a heteroatom and may have
 10 substituent(s).

6. The agent according to claim 1, wherein the compound having an angiotensin II antagonistic activity is Losartan, Eprosartan, Candesartan cilexetil, Candesartan,
 15 Valsartan, Telmisartan, Irbesartan, Olmesartan or Tasosartan.

7. The agent according to claim 1, wherein the compound having an angiotensin II antagonistic activity is 2-ethoxy-1-[[2'-(1H-tetrazole-5-yl)biphenyl-4-

← Candesartan

yl)methyl]benzimidazole-7-carboxylic acid.

8. The agent according to claim 1, wherein the compound having an angiotensin II antagonistic activity is 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazole-5-yl)biphenyl-4-yl)methyl]benzimidazole-7-carboxylate.

*candesartan
cilener*

9. The agent according to claim 1, wherein the compound having an angiotensin II antagonistic activity is 2-ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazole-3-yl)biphenyl-4-yl)methyl]benzimidazole-7-carboxylic acid.

10. The agent according to claim 1, wherein the troubles following cerebrovascular disorder are nerve symptoms.

11. The agent according to claim 1, wherein the troubles following cerebrovascular disorder are mental symptoms.

12. The agent according to claim 1, wherein the troubles following cerebrovascular disorder are subjective symptoms.

13. The agent according to claim 1, wherein the troubles following cerebrovascular disorder are obstacles in activities of daily living.

14. A method for preventing recurrence of cerebrovascular disorder in mammals which comprises administering an effective amount of a compound having an

20031398 01803

angiotensin II antagonistic activity, a prodrug thereof or a salt thereof to the mammals.

15. A method for ameliorating troubles following cerebrovascular disorder or inhibiting progress thereof in mammals which comprises administering an effective amount of a compound having an angiotensin II antagonistic activity, a prodrug thereof or a salt thereof to the mammals.

10 16. Use of a compound having an angiotensin II antagonistic activity, a prodrug thereof or a salt thereof for manufacturing a pharmaceutical preparation for preventing recurrence of cerebrovascular disorder.

15 17. Use of a compound having an angiotensin II antagonistic activity, a prodrug thereof or a salt thereof for manufacturing a pharmaceutical preparation for ameliorating troubles following cerebrovascular disorder or inhibiting progress thereof.

20031398 011802

add
A2